Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  MannKind Corporation    MNKD

Delayed Quote. Delayed  - 07/22 10:00:00 pm
0.9981 USD   +0.98%
07/08 MANNKIND : to Present at Cantor Fitzgerald's 2nd Annual Healthcare C..
07/08 MannKind Corporation to Present at Cantor Fitzgerald’s 2nd ..
06/12 MannKind Announces Late-Breaking Data Reinforcing Faster Onset an..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MannKind Corporation : MNKD, MU, ALXN and GMCR added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 07/16/2013 - Equity Profile Report initiates its NASDAQ Active Stock Watch List adding MannKind Corp. (NASDAQ:MNKD), Micron Technology Inc. (NASDAQ:MU), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Green Mountain Coffee Roasters, Inc. (NASDAQ:GMCR),

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States closed up in its previous session (+6.47%) on 7,469,136 shares traded. MannKind Corp. (NASDAQ:MNKD) is currently up (+310.99%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MNKD&SubId=AW

Micron Technology Inc. (NASDAQ:MU) a company that together with its subsidiaries, engages in manufacturing and marketing semiconductor devices worldwide closed up in its previous session (+2.99%) on 29,731,748 shares traded after Micron Technology Inc reported its Financials. Micron Technology Inc. (NASDAQ:MU) is currently up (+155.62%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Micron Technology Inc. (NASDAQ:MU)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MU&SubId=AW

Also mentioned in Equity Profile Report?s NASDAQ Active Stock Watch List and Investor Poll was: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Green Mountain Coffee Roasters, Inc. (NASDAQ:GMCR), Groupon, Inc. (NASDAQ:GRPN) and Zynga, Inc. (NASDAQ:ZNGA)

To see what other investors are saying about: ALXN, GMCR, GRPN, ZNGA

Click here: http://www.equityprofilereport.com/PR.aspx?stock=ALXN-GMCR-GRPN-ZNGA&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report

editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MANNKIND CORPORATION
07/08 MANNKIND : to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/08 MannKind Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healt..
07/07 MANNKIND : Patent Application Titled "Insufflation Apparatus and Methods" Publis..
06/12 MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Du..
06/10 MannKind Announces Collaboration with JDRF
05/10 MANNKIND : Announces Pricing of Registered Direct Public Offering of Common Stoc..
05/10 MannKind Announces Pricing of Registered Direct Public Offering of Common Sto..
05/09 MANNKIND CORP : Results of Operations and Financial Condition, Financial Stateme..
05/09 MANNKIND : reports 1Q loss
05/09 MannKind Corporation Reports 2016 First Quarter Financial Results
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/22 MannKind - Afrezza Sales Pacing Below My Bearish Line - Reality May Sting
07/15 MannKind - Afrezza Scripts Starting Off Modestly On Relaunch
07/13 MannKind - Can New Afrezza Sample And Titration Packs Boost Sales
07/08 MANNKIND : Afrezza Relaunch Starts Now
06/30 MANNKIND 2.0 LAUNCH : No Room For Error
Advertisement
Financials ($)
Sales 2016 3,78 M
EBIT 2016 -60,3 M
Net income 2016 -100 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 126x
Capi. / Sales 2017 31,6x
Capitalization 477 M
More Financials
Chart MANNKIND CORPORATION
Duration : Period :
MannKind Corporation Technical Analysis Chart | MNKD | US56400P2011 | 4-Traders
Full-screen chart
Technical analysis trends MANNKIND CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 0,15 $
Spread / Average Target -85%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Matthew J. Pfeffer CEO, CFO, Director, VP & Head-Investor Relations
Kent Kresa Chairman
Raymond W. Urbanski Chief Medical Officer & Vice President
Joseph Kocinsky Chief Technology Officer & Vice President
Ronald J. Consiglio Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MANNKIND CORPORATION-31.17%477
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
CELGENE CORPORATION-10.22%83 285
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
More Results